Who founded EnClear Therapies?

EnClear Therapies was founded by Anthony DePasqua.

Who are EnClear Therapies's investors?

EnClear Therapies's investors include 20/20 HealthCare Partners LLC, Flucas Ventures, Tachyon Ventures, VU Venture Partners, Dolby Family Ventures.

How much funding has EnClear Therapies raised?

EnClear Therapies has disclosed $718.3K raised across 1 round.

Where is EnClear Therapies headquartered?

EnClear Therapies is headquartered in Cambridge, US.

EnClear Therapies

Cambridge, US · Delaware corporation · 5 known investors

encleartherapies.com ↗

EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Anthony DePasquainFounder

Jason CammNamed on SEC filing

Kasper RoetNamed on SEC filing

Tony DePasquaPresident & CEO

Kevin KalishCOO

Marcie GlicksmanVP Biology

William GormleyCMO

Board

Jonathan FlemingBoard director

Investors · 5

20/20 HealthCare Partners LLCAuburndalevia Hillel Bachrach · led

Flucas VenturesJupiter · $100K – $5Mvia Ashley Flucas · inferred

Tachyon VenturesLos Angeles

VU Venture PartnersSan Francisco · $200K – $1M

Dolby Family VenturesreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$718.3K disclosed across 1 round · 2024

▶$718.3KraisedMar 2024 · 8 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Jonathan FlemingDirector
Jason CammDirector
Kasper RoetDirector
Anthony DePasquaExecutive Officer, Director

Offering amount: $2M
Amount sold: $718.3K
First sale: Feb 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Intracellular Therapies4 shared keywordsIntra-Cellular Therapies develops treatments for neuropsychiatric, neurologic, and related disorders, including its product CAPLYTA. The company is now part of Johnson & Johnson.

Clinicaltrialsarena3 shared keywordsClinical Trials Arena is an online news and information publication covering the clinical trials industry, including trends, regulatory developments, and industry events. It serves professionals working in pharmaceutical and clinical research.

Companies competing with EnClear Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does EnClear Therapies do?: EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.
Who founded EnClear Therapies?: EnClear Therapies was founded by Anthony DePasqua.
Who are EnClear Therapies's investors?: EnClear Therapies's investors include 20/20 HealthCare Partners LLC, Flucas Ventures, Tachyon Ventures, VU Venture Partners, Dolby Family Ventures.
How much funding has EnClear Therapies raised?: EnClear Therapies has disclosed $718.3K raised across 1 round.
Where is EnClear Therapies headquartered?: EnClear Therapies is headquartered in Cambridge, US.